Phase 3 Trial For Opevesostat A CYP11A1 Inhibitor in mCRPC

/in , , /by

Opevesostat, a first-in-class CYP11A1 inhibitor, blocks the first step of steroid hormone production, eliminating all ligands that activate mutant androgen receptors in metastatic castration-resistant prostate cancer (mCRPC). The Phase 3 MK-5684-004 trial tests it against standard next-generation hormonal agents (NHAs, like abiraterone, enzalutamide, …) switching in 1,500 patients progressed on one prior NHA, with rPFS […]

Read more

A-CAR032: a STEAP2-Targeted Armored CAR-T Enters First-in-Human Trial for Advanced Prostate Cancer

/in , , /by

A new Phase 1 clinical trial is testing A-CAR032, a CAR-T cell therapy, in patients with metastatic castration-resistant prostate cancer, or mCRPC. This first-in-human study targets STEAP2, a protein found on nearly all prostate cancer cells, including those that have spread to bones and lymph nodes. Prostate cancer creates a tough environment for immune cells […]

Read more

SL-28 Phase 1/2 Trial: A Potential Breakthrough for Advanced Solid Tumors

/in , , , /by

SL-28 is a new type of donor cell therapy called Leukocyte-Tells. These cells come from healthy donors and get prepared outside the body to better fight cancer. They make more cancer-killing compounds, eat tumor cells, release enzymes, produce helpful signals, and move well toward tumors. Unlike other cell therapies, SL-28 does not need to match […]

Read more

UPDATE: SECuRE Trial Phase 2 Shows 67% PSA50 Response in Heavily Pre-Treated mCRPC

/in , , /by

The latest interim update from the SECuRE trial reinforces the impression that copper‑67 PSMA targeting is emerging as a credible contender in the mCRPC radioligand space, with consistent PSA responses and a clean safety profile in a small but challenging population. The Safety Review Committee has endorsed continuation of the Phase 2 cohort expansion without […]

Read more

Phase 1 Trial: STEAP1 CAR‑T Plus Enzalutamide A New Immune Approach for mCRPC

/in , , , /by

STEAP1 is a protein that sits on the surface of many prostate cancer cells, especially in advanced metastatic disease. Because it is abundant on cancer cells and much less present in normal tissues, STEAP1 looks like a promising “flag” that engineered immune cells can use to distinguish tumor from healthy organs. ​ The treatment being […]

Read more

NADIR Model: A Prognostic Framework for Early Treatment Stratification in mHSPC

/in /by

Doctors treating advanced prostate cancer start patients on hormone therapy plus a drug called an androgen receptor pathway inhibitor, or ARPI. These drugs work well for most men, but doctors must wait six months to check if the PSA blood level drops very low, to 0.2 nanograms per milliliter or less. This low PSA strongly […]

Read more

ANDROMEDA: Phase 1/2 Trial of AZD9750 AR Degrader in Metastatic Prostate Cancer

/in , , , /by

The ANDROMEDA trial, a first-in-human Phase 1/2 study, is evaluating AZD9750, a novel androgen receptor (AR) PROTAC, in men with metastatic castration-resistant prostate cancer (mCRPC). PROTACs represent a paradigm shift in targeted therapy: unlike traditional AR inhibitors that merely block the receptor’s activity, AZD9750 recruits cellular machinery to completely degrade the AR protein, potentially overcoming […]

Read more

GSK5471713: An Investigational AR Degrader Targeting Late-Stage Prostate Cancer Resistance

/in , , , /by

Note: This article treats GSK5471713 as an androgen receptor (AR) degrader based on GSK’s official clinical trial registry classification and inclusion/exclusion criteria. While confident in the AR degrader designation from the sponsor’s documentation, the specific degradation mechanism (PROTAC, SARD, or other platform) remains undisclosed in publicly available sources at the moment. GSK5471713 is an investigational […]

Read more